The sensitization test

The sensitization test is the second, except for the irritation test, in vivo biological endpoint to be evaluated any type of medical device required by ISO 10993-1: 2018.

In ISO 10993-10 three types of sensitization tests are mentioned: Guinea pig maximization test (GPMT), Buehler test, and Local lymph node assay (LLNA). The appropriate method should be chosen taking into account the application, properties, and intended region of registration of the medical device.

We carry out all of the mentioned methods for testing sensitization. Contact us to choose the right method for your device!

See more

ISO 10993-1:2025: Enhanced Characterization, Clearer Risk Logic

The 2025 revision keeps biological evaluation firmly inside ISO 14971 risk management and across the full device life cycle. Your…

ISO 10993-1:2025: Risk Management Integration and Exposure Duration

ISO 10993-1:2025 embeds the biological evaluation within ISO 14971’s risk-management framework. The standard explicitly requires identifying biological hazards, estimating their…

Preparing for Biocompatibility Testing: Strategic Considerations for Medical Device Manufacturers

Biocompatibility testing is essential for every medical device, ensuring safety, regulatory approval, and market success. The process, however, can be…

In Vitro & In Vivo: Strategic Insights for Medical Device Leaders

Biocompatibility testing is not just a regulatory requirement—it is a cornerstone of medical device safety, market approval, and long-term trust….

Biocompatibility Requirements for Wearable Medical Devices: Unique Considerations

Wearable medical devices are transforming healthcare with continuous monitoring, real-time diagnostics, and improved patient engagement. However, their design introduces distinct…

Proactive Planning: Combining Biocompatibility with Other Preclinical Testing Needs

Biocompatibility testing is a vital part of preclinical evaluation, but it’s just one piece of the larger puzzle. Manufacturers often…